Locoregional lactate dehydrogenase inhibition potentiates therapy and overcomes treatment resistance in hepatocellular carcinoma
Authors:
- 30 April 2026
- journal article
- research article
- Published by Wolters Kluwer Health in Hepatology
- Vol. 84 (6) , 1691-1707
Abstract
Background and Aims: Metabolic inhibitors have demonstrated limited efficacy for cancer therapy due to metabolic plasticity and systemic toxicity. Locoregional therapies (LRT), such as transarterial embolization (TAE) or transarterial chemoembolization (TACE), generate ischemic stress that reprograms the tumor microenvironment (TME) toward glycolytic dependency, creating an opportunity to sensitize hepatocellular carcinoma (HCC) to metabolic inhibition. This study investigated whether pharmacologic inhibition of lactate dehydrogenase (LDH) with NCATS-SM1441 could exploit TAE-induced metabolic vulnerabilities to improve therapeutic efficacy in HCC. Approach and Results: Human HCC cell lines were exposed to replete or ischemic (TAE-like) conditions and treated with the LDH inhibitor NCATS-SM1441. Glucose/lactate flux, adenosine triphosphate (ATP) levels, and viability were assessed. In vivo, a diethylnitrosamine (DEN)-induced rat HCC model was treated with intra-arterial NCATS-SM1441, TAE, or their combination. Drug distribution, tumor metabolism, necrosis, and survival were analyzed using mass spectrometry imaging, histopathology, T2-weighted magnetic resonance imaging (MRI), and survival metrics. Ischemic conditions induced LDHA expression and glycolytic flux, enhancing susceptibility to LDH inhibition. The combination of intra-arterial NCATS-SM1441 before embolization increased intratumoral drug accumulation, reduced systemic exposure, and synergized with TAE to suppress lactate production, promote tumor necrosis, and significantly extend local progression-free survival. Conclusions: TAE conditions the TME to create a therapeutically targetable glycolytic dependency. Combining TAE with LDH inhibition overcomes key limitations of metabolic inhibitors as monotherapies, enhancing local control and survival with minimal systemic toxicity, supporting integration of metabolism-targeted agents with LRT for unresectable HCC.Keywords
This publication has 38 references indexed in Scilit:
- Targeting lactate metabolism in the tumor microenvironment: Immunomodulation and prospects for antitumor therapyInternational Immunopharmacology, 2025
- Metabolic programming and immune suppression in the tumor microenvironmentCancer Cell, 2023
- GCN2 inhibition sensitizes arginine-deprived hepatocellular carcinoma cells to senolytic treatmentCell Metabolism, 2022
- Deletion of Lactate Dehydrogenase-A Impairs Oncogene-Induced Mouse Hepatocellular Carcinoma DevelopmentCellular and Molecular Gastroenterology and Hepatology, 2022
- Hyperpolarized Metabolic Imaging Detects Latent Hepatocellular Carcinoma Domains Surviving Locoregional TherapyHepatology, 2020
- Integrated Proteogenomic Characterization of HBV-Related Hepatocellular CarcinomaCell, 2019
- Targeting Metabolism for Cancer TherapyCell Chemical Biology, 2017
- Segmental Transarterial Embolization in a Translational Rat Model of Hepatocellular CarcinomaJournal of Vascular and Interventional Radiology, 2015
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- User-guided 3D active contour segmentation of anatomical structures: Significantly improved efficiency and reliabilityNeuroImage, 2006